ERBB2 and gastric cancer: If KEYNOTE-811 demonstrates a survival benefit in the pembrolizumab arm and the DESTINY-Gastric03 study shows efficacy and acceptable safety, a clinical trial comparing trastuzumab with trastuzumab deruxtecan alongside the combination of an immune checkpoint inhibitor and chemotherapy will be conducted, the most successful of which may become the gold standard for the future first-line treatment of HER2-positive gastric cancer.